<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Biologic</title>
	<atom:link href="http://www.tapanray.in/tag/biologic/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Ticking Some Right Boxes Biosimilar Drugs’ Acceptance Gaining Steam in India</title>
		<link>http://www.tapanray.in/ticking-some-right-boxes-biosimilar-drugs-acceptance-gaining-steam-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=ticking-some-right-boxes-biosimilar-drugs-acceptance-gaining-steam-in-india</link>
		<comments>http://www.tapanray.in/ticking-some-right-boxes-biosimilar-drugs-acceptance-gaining-steam-in-india/#comments</comments>
		<pubDate>Sun, 24 Sep 2023 06:26:00 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[acceptance]]></category>
		<category><![CDATA[arbitrage]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Boxes]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[initiatives]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[stakeholder]]></category>
		<category><![CDATA[support]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[ticking]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10828</guid>
		<description><![CDATA[Looking at a broader canvas, on September 19, 2023, a credible international report flashed a headline, ‘Biosimilars making inroads into Humira sales, but docs still cautious on switching: Spherix.’ This is based on a survey of U.S. healthcare specialists, including 80 dermatologists, &#8230; <a href="http://www.tapanray.in/ticking-some-right-boxes-biosimilar-drugs-acceptance-gaining-steam-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/ticking-some-right-boxes-biosimilar-drugs-acceptance-gaining-steam-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Meeting India’s Unmet Biologic Drug Needs Some Global Synergy Evident &#8211; But Patients Need More</title>
		<link>http://www.tapanray.in/meeting-indias-unmet-biologic-drug-needs-some-global-synergy-evident-but-patients-need-more/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=meeting-indias-unmet-biologic-drug-needs-some-global-synergy-evident-but-patients-need-more</link>
		<comments>http://www.tapanray.in/meeting-indias-unmet-biologic-drug-needs-some-global-synergy-evident-but-patients-need-more/#comments</comments>
		<pubDate>Mon, 17 Jul 2023 00:00:32 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[Availability]]></category>
		<category><![CDATA[awareness]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[Biosimilar. drugs]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Coverage]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[needs]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[physicians]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[unmet]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10799</guid>
		<description><![CDATA[Many reports have vindicated the rapidly growing importance of biologic drugs in the treatment of a wide range of complex ailments. These include autoimmune diseases, cancers, hormonal irregularities, anemia, and to prevent various diseases such as vaccines, have drawn healthcare &#8230; <a href="http://www.tapanray.in/meeting-indias-unmet-biologic-drug-needs-some-global-synergy-evident-but-patients-need-more/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/meeting-indias-unmet-biologic-drug-needs-some-global-synergy-evident-but-patients-need-more/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A Game-Changing Non-Covid Drug Approval In the Pandemic Milieu</title>
		<link>http://www.tapanray.in/a-game-changing-non-covid-drug-approval-in-the-pandemic-milieu/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-game-changing-non-covid-drug-approval-in-the-pandemic-milieu</link>
		<comments>http://www.tapanray.in/a-game-changing-non-covid-drug-approval-in-the-pandemic-milieu/#comments</comments>
		<pubDate>Mon, 11 Oct 2021 00:00:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[approval]]></category>
		<category><![CDATA[barrier]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[consumers]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[designation]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Glargine]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[insuline]]></category>
		<category><![CDATA[interchangeable]]></category>
		<category><![CDATA[Lantus]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[milieu]]></category>
		<category><![CDATA[original]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Semglee]]></category>
		<category><![CDATA[superior]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10595</guid>
		<description><![CDATA[Amid high decibel deliberations on Covid-19 pandemic, something similar to groundbreaking happened &#8211; involving Biosimilar drugs, in just a couple of months ago. On July 28, 2021, in the Eldorado of the pharma industry, the US-FDA approved  the first ‘interchangeable’ biosimilar drug, &#8230; <a href="http://www.tapanray.in/a-game-changing-non-covid-drug-approval-in-the-pandemic-milieu/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-game-changing-non-covid-drug-approval-in-the-pandemic-milieu/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Spirit Behind Drug Patent Grant: Secondary Patents: Impact on Drug Access</title>
		<link>http://www.tapanray.in/spirit-behind-drug-patent-grant-secondary-patents-impact-on-drug-access/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=spirit-behind-drug-patent-grant-secondary-patents-impact-on-drug-access</link>
		<comments>http://www.tapanray.in/spirit-behind-drug-patent-grant-secondary-patents-impact-on-drug-access/#comments</comments>
		<pubDate>Mon, 09 Sep 2019 00:00:45 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biopharma]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[entry]]></category>
		<category><![CDATA[Grant]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[needs]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Patents Act]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[secondary]]></category>
		<category><![CDATA[Spirit]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[unmet]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9701</guid>
		<description><![CDATA[For more effective treatment against existing diseases, besides combating new or a more complicated form of existing ailments with precision, drug innovation is absolutely necessary and on an ongoing basis. This makes innovative drugs so important for the population, globally. &#8230; <a href="http://www.tapanray.in/spirit-behind-drug-patent-grant-secondary-patents-impact-on-drug-access/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/spirit-behind-drug-patent-grant-secondary-patents-impact-on-drug-access/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is India A Success Story With Biosimilar Drugs?</title>
		<link>http://www.tapanray.in/is-india-a-success-story-with-biosimilar-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-india-a-success-story-with-biosimilar-drugs</link>
		<comments>http://www.tapanray.in/is-india-a-success-story-with-biosimilar-drugs/#comments</comments>
		<pubDate>Mon, 25 Feb 2019 00:00:25 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[commercial]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[labyrinth]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pathways]]></category>
		<category><![CDATA[perception]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[revenue]]></category>
		<category><![CDATA[story]]></category>
		<category><![CDATA[success]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[uncertainty]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9422</guid>
		<description><![CDATA[How Indian generic companies are expanding, if not shifting their business focus on biosimilar and complex generic drugs, may be a current trend of general discourse &#8211; but the initiative is not a current one. This journey commenced decades ago &#8230; <a href="http://www.tapanray.in/is-india-a-success-story-with-biosimilar-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-india-a-success-story-with-biosimilar-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A ‘Toxin’ Delaying Success of Biosimilar Drugs</title>
		<link>http://www.tapanray.in/a-toxin-delaying-success-of-biosimilar-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-toxin-delaying-success-of-biosimilar-drugs</link>
		<comments>http://www.tapanray.in/a-toxin-delaying-success-of-biosimilar-drugs/#comments</comments>
		<pubDate>Mon, 06 Aug 2018 00:00:46 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[commissioner]]></category>
		<category><![CDATA[delay]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Glaritus]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[immunogenicity]]></category>
		<category><![CDATA[Interchangeability]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[Lantus]]></category>
		<category><![CDATA[launch]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[original]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Self]]></category>
		<category><![CDATA[serving]]></category>
		<category><![CDATA[success]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Toxin]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[wockhardt]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9086</guid>
		<description><![CDATA[The above comment, although sounds a bit harsh, was made recently by none other than Scott Gottlieb - the Food and Drug Administration Commissioner of the United States. He expressed his anguish while explaining the reasons for a delayed launch of several important &#8230; <a href="http://www.tapanray.in/a-toxin-delaying-success-of-biosimilar-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-toxin-delaying-success-of-biosimilar-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>&#8216;Rigged&#8217; Payment System Limits Biosimilar Access</title>
		<link>http://www.tapanray.in/rigged-payment-system-limits-biosimilar-access/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=rigged-payment-system-limits-biosimilar-access</link>
		<comments>http://www.tapanray.in/rigged-payment-system-limits-biosimilar-access/#comments</comments>
		<pubDate>Mon, 02 Apr 2018 00:00:05 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[commissioner]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[el dorado]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Interchangeability]]></category>
		<category><![CDATA[large]]></category>
		<category><![CDATA[largest]]></category>
		<category><![CDATA[launch]]></category>
		<category><![CDATA[litigations]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[molecule]]></category>
		<category><![CDATA[original]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[rigged]]></category>
		<category><![CDATA[small]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[Zarxio]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8908</guid>
		<description><![CDATA[As often discussed, market entry of biosimilars, in general, brings a new hope not just for many patients, but also to biosimilar drug manufacturers &#8211; planning to get marketing approvals of these drugs in the United States, the El Dorado &#8230; <a href="http://www.tapanray.in/rigged-payment-system-limits-biosimilar-access/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/rigged-payment-system-limits-biosimilar-access/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Patent Expiry No Longer End of The Road</title>
		<link>http://www.tapanray.in/patent-expiry-no-longer-end-of-the-road/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=patent-expiry-no-longer-end-of-the-road</link>
		<comments>http://www.tapanray.in/patent-expiry-no-longer-end-of-the-road/#comments</comments>
		<pubDate>Sun, 03 Dec 2017 23:30:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Adalimumab]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[end]]></category>
		<category><![CDATA[exemptia]]></category>
		<category><![CDATA[expiry]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[Humira]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Infliximab]]></category>
		<category><![CDATA[labyrinth]]></category>
		<category><![CDATA[Lantus]]></category>
		<category><![CDATA[MabThera]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Remicade]]></category>
		<category><![CDATA[Rituxan]]></category>
		<category><![CDATA[Rituximab]]></category>
		<category><![CDATA[Road]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trastuzumab]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[Zydus]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8600</guid>
		<description><![CDATA[Who says that the phenomenal success of blockbuster drugs is mostly eaten away by  ‘look-alikes’ of the same, immediately after respective patent expiry? It doesn’t seem to be so any longer, not anymore! Several examples will vindicate this emerging trend. &#8230; <a href="http://www.tapanray.in/patent-expiry-no-longer-end-of-the-road/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/patent-expiry-no-longer-end-of-the-road/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Improving Patient Access To Biosimilar Drugs: Two Key Barriers</title>
		<link>http://www.tapanray.in/improving-patient-access-to-biosimilar-drugs-two-key-barriers/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=improving-patient-access-to-biosimilar-drugs-two-key-barriers</link>
		<comments>http://www.tapanray.in/improving-patient-access-to-biosimilar-drugs-two-key-barriers/#comments</comments>
		<pubDate>Mon, 31 Jul 2017 00:00:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[approval]]></category>
		<category><![CDATA[barrier]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[CCI]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[evidence]]></category>
		<category><![CDATA[framework]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[immunogenicity]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[Interchangeability]]></category>
		<category><![CDATA[interchangeable]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[middle]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[path]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8334</guid>
		<description><![CDATA[Novel biologic medicines have unlocked a new frontier offering more effective treatment for a host of chronic and life-threatening diseases, such as varieties of cancer, rheumatoid arthritis and diabetes, to name just a few. However, these drugs being hugely expensive, &#8230; <a href="http://www.tapanray.in/improving-patient-access-to-biosimilar-drugs-two-key-barriers/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/improving-patient-access-to-biosimilar-drugs-two-key-barriers/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is Criticizing Pharma Now Just A Fad?</title>
		<link>http://www.tapanray.in/is-criticizing-pharma-now-just-a-fad/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-criticizing-pharma-now-just-a-fad</link>
		<comments>http://www.tapanray.in/is-criticizing-pharma-now-just-a-fad/#comments</comments>
		<pubDate>Sun, 09 Oct 2016 23:46:28 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[ABBvie]]></category>
		<category><![CDATA[Amjevita]]></category>
		<category><![CDATA[Approach]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[criticizing]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Fad]]></category>
		<category><![CDATA[Humira]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[interchangeable]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[profit]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7861</guid>
		<description><![CDATA[Is criticizing pharma now just a fad of its stakeholders? Fathoming the right answer to this seemingly simple question may not be too easy, either, for some. The task could even be more onerous, especially when the global ‘researched based’ &#8230; <a href="http://www.tapanray.in/is-criticizing-pharma-now-just-a-fad/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-criticizing-pharma-now-just-a-fad/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
